

A Unique Cause of Anion Gap Metabolic Acidosis: Euglycemia DKA.

Ross Cohen DO, PGY-4

Kevin Weaver D.O.,FACOEP

Lehigh Valley Health Network, kevin_r.weaver@lvhn.org

Follow this and additional works at: <http://scholarlyworks.lvhn.org/emergency-medicine>



Part of the [Emergency Medicine Commons](#)

Published In/Presented At

Cohen, R. Weaver, K. (2017, April 18). *A Unique Cause of Anion Gap Metabolic Acidosis: Euglycemia DKA*. Poster Presented at: ACOEPS SPRING SEMINAR, Bonita Springs, FL.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Ross Cohen, DO, PGY-4 and Kevin Weaver, DO, Program Director
Lehigh Valley Health Network, Allentown, Pennsylvania

INTRODUCTION

SGLT-2 inhibitors are a new class of oral diabetes medication that have been associated with a rare complication- euglycemic DKA. This case illustrates the importance of recognizing this clinical entity that can lead to a gapped metabolic acidosis in the setting of a normal glucose level.

HISTORY

CHIEF COMPLAINT: Vomiting, weakness, palpitations

HPI: A 34 year old female with a past medical history significant for AML s/p multiple past chemo treatments, DM Type 2, HTN, anxiety and depression presented to the ED with head to toe generalized body aches x 4 days. Although her complaints ranged from chest pain to abdominal pain, she specifically came to the ED for evaluation of her fatigue after a night of vomiting >8 (non bloody) episodes and decreased po intake.

PAST MEDICAL & SURGICAL HISTORY: Dx w AML in 2011, anxiety, depression, DM II, Hysterectomy

SOCIAL HISTORY: No smoking, alcohol or illicit drug use, no history of SI/HI, poorly compliant with glucose monitoring diabetes

MEDICATIONS:

- Wellbutrin
- Aspirin
- Invokana
- Klonopin
- Levemir
- Victoza

ALLERGIES: Ambien

PHYSICAL EXAM

VITAL SIGNS: BP - 145/85 HR - 165 RR - 18 T - 99 F O₂ - 99% RA

GEN: Anxious, moaning in room

HEENT: PERRLA, EOMI, moderate DMM

PULM: CTABL.

CARDS: Sinus tachy, no M/R/G. Good distal pulses.

ABD: Soft, nondistended, nontender. +BS.

SKIN: Warm, dry, no rashes.

NEURO: AAO x 3, CN II-XII intact.

PSYCH: agitated, anxious, tearful.

LABORATORY STUDIES



AST: 87 **UA:** + ketones **TROP:** <0.02 **LACTATE:** 2
ALT: 47 **UPreg:** Negative **TSH:** 1.39 **AG:** 16

DIFFERENTIAL DIAGNOSIS

Having an anion gap metabolic acidosis of 16 with a bicarbonate of 8, the etiology was not readily apparent with the patient's normal lactate, absence of fever and only mildly elevated serum glucose 220.

- Infectious
- Structural (PE)
- Toxicologic

Anion Gap Metabolic Acidosis
Methanol
Uremia
Diabetic ketoacidosis
Paraldehyde
Iron, isoniazid
Lactic acidosis
Ethylene glycol
Salicylates

EXPANDED LABS

VBG: 6.91/34/99/7/95 **UDS:** + opiates **ETOH:** Neg **BC x 2:** Neg
ACETONE: 47 **ASA:** 4 **TOX alcohols:** Neg **D-dimer:** 0.68
BHB: 7.16 **APAP:** <2 **RVP:** Neg **CXR:** Nad
EKG: Sinus145

HOSPITAL COURSE OF CARE

Her expanded labs ultimately revealed a worsening acidosis with positive blood and urine ketones, leading to the diagnosis of euglycemic DKA. She was admitted to the ICU on both an insulin and bicarbonate drip with dextrose containing fluids and frequent glucose checks. After her gap closed, her home medications revealed the culprit of this unique cause of DKA, her SGLT2 inhibitor which was immediately discontinued.

DISCUSSION

EUGLYCEMIC DKA: Although DKA is classically taught to include acidosis, hyperglycemia and increased plasma ketones, euglycemic DKA is basically DKA without the hyperglycemia. It is a more rare diagnosis; however, ED providers should have it on their differential of AGMA, specifically in diabetic patients on SGLT-2 inhibitors.

MECHANISM:




Image Modified From:
Ogawa W et al. J Diabetes Investig 2016

SGLT-2 inhibitors block sodium glucose co transporters in the proximal renal tubules which promotes glucose excretion. Just as in normal diabetic ketotic states, when the body cannot use blood glucose for energy, ketones and acidosis will ensue; however, since the overall glucose levels in the body are lower, the pt will be euglycemic.

TREATMENT: The treatment of euDKA is practically identical to the management of DKA with a few added caveats.

- IV fluids with dextrose
- IV Insulin drip
- Frequent Glucose monitoring
- Discontinue all SGLT-2 inhibitors

REFERENCES:

- Joseph F, et al. Starvation-induced True Diabetic Euglycemic Ketoacidosis in Severe Depression. J Gen Intern Med. 2009 Jan; 24(1): 129-131.
- Ogawa W, et al. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. Journal of Diabetes Investigation. 2016; 7(2):135-138.
- Rosenstock J, et al. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT1 Inhibitors. Diabetes Care. 2015 Sep; 38(9):1638-42.
- Kasichayanula S, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2. Clinical Pharmacokinetics January 2014; 53(1): 17-27.
- Liao Z, et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol. 2008 Jun; 65(6):893-907.
- Yamanaka H, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 2004 May; 14(5):329-32.
- Pattarawongsa A, et al. Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions. Drug Metab Dispos. 2015 Oct; 43(10):1468-76.
- <http://care.diabetesjournals.org/content/38/9/1638>
- <http://care.diabetesjournals.org/content/38/9/1687>
- <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488998/>
- <http://rebelem.com/tag/euglycemic-dka/>